Evidence map›Paper›PMID 41727444›Full record

ArticleFrontiers in immunology2026

Glycosaminoglycan binding to soluble CX3CL1 impacts monocyte migration

Maria Ennemoser, Paula Peinsipp, Tihana Novak, Clara Matteini, Dorian Tauschmann, Tanja Gerlza, Andreas J Kungl

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maria Ennemoser *Institute of Pharmaceutical Sciences, Department for Pharmaceutical Chemistry, Karl-Franzens-University of Graz, Graz, Austria.
Paula Peinsipp *Institute of Pharmaceutical Sciences, Department for Pharmaceutical Chemistry, Karl-Franzens-University of Graz, Graz, Austria.
Tihana NovakInstitute of Pharmaceutical Sciences, Department for Pharmaceutical Chemistry, Karl-Franzens-University of Graz, Graz, Austria.
Clara MatteiniInstitute of Pharmaceutical Sciences, Department for Pharmaceutical Chemistry, Karl-Franzens-University of Graz, Graz, Austria.
Dorian TauschmannInstitute of Pharmaceutical Sciences, Department for Pharmaceutical Chemistry, Karl-Franzens-University of Graz, Graz, Austria.
Tanja GerlzaInstitute of Pharmaceutical Sciences, Department for Pharmaceutical Chemistry, Karl-Franzens-University of Graz, Graz, Austria.
Andreas J KunglInstitute of Pharmaceutical Sciences, Department for Pharmaceutical Chemistry, Karl-Franzens-University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In addition to providing shear-resistant cell-cell adhesion in its natural membrane-bound form, the soluble variant of CX3CL1 (or fractalkine) promotes strong cell migration through signaling via its unique G-protein-coupled receptor CX3CR1 on monocytes, macrophages, T-cells, and NK-cells. To induce cell migration, most chemokines benefit from their interaction with the heterogenous group of glycosaminoglycans (GAGs), which act as coreceptors in chemotactic processes. While the interaction of many chemokines with their GAG counterparts has been investigated in detail, the potential interaction of CX3CL1 and GAGs has not yet received sufficient attention. Results: Here, we show that the bioactive N-terminal, soluble chemokine domain of CX3CL1 (cdCX3CL1) binds to heparan sulfate (HS) as well as to dermatan sulfate (DS or CS-B), exhibiting Kd-values in the mid nanomolar range. Moreover, the removal of monocyte-surface HS reduced cdCX3CL1-induced cell migration, thereby strongly indicating a potential biological relevance of CX3CL1 binding to GAGs. Interaction studies taking into account the extracellular receptor-peptide of CX3CR1 showed that, in addition to binding CX3CL1, CX3CR1 was found to bind to HS as well. Cross-linking cdCX3CL1 and the CX3CR1 peptide led to a ten-fold higher HS binding affinity compared to the isolated proteins. Discussion: These findings further strengthen the assumption of an extended interaction network, in which GPCR, chemokine, and GAGs affect each other simultaneously.

Indexed as

Cell MovementChemokine CX3CL1GlycosaminoglycansMonocytesCX3C Chemokine Receptor 1Dermatan SulfateHeparan SulfateHumansProtein BindingChemokine CX3CL1CX3C Chemokine Receptor 1CX3CL1 protein, humanDermatan SulfateGlycosaminoglycansHeparan Sulfatechemokinechemokine receptorfractalkineglycosaminoglycanheparan sulfatemonocyte

Identifiers

PMID41727444
PMCPMC12920477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.